Galapagos develops therapies with proprietary, novel modes-of-action. Filgotinib, Galapagos' most advanced novel mode-of-action program, was discovered using our proprietary target discovery technology, and is being developed by Gilead and Galapagos in several inflammatory indications. Galapagos is progressing multiple programs in inflammation, cystic fibrosis, metabolic diseases, fibrosis, and other disease areas. Galapagos is listed on Euronext Amsterdam and Brussels and on the NASDAQ; all with the ticker symbol GLPG. Source
No articles found.
At Delee were fundamentally changing not only the way cancer is detected but also...
At Delee were fundamentally changing not only ...
BioLineRx is a clinical-stage biopharmaceutical company focused on oncology. The C...
BioLineRx is a clinical-stage biopharmaceutical...
LifeBridge 10000, LLC specializes in extending and improving the quality of life f...
LifeBridge 10000, LLC specializes in extending ...
Horizon is a biopharmaceutical company focused on researching, developing and comm...
Horizon is a biopharmaceutical company focused ...
Merus is a clinical-stage immuno-oncology company developing innovative full-lengt...
Merus is a clinical-stage immuno-oncology compa...
Edesa Biotech Inc. is a clinical-stage biopharmaceutical company founded by expert...
Edesa Biotech Inc. is a clinical-stage biopharm...
Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical c...
Corbus Pharmaceuticals Holdings, Inc. is a Phas...
Join the National Investor Network and get the latest information with your interests in mind.